Last Update: May 06, 2023
A First-in-patient Phase I/II Clinical Study to Investigate the Safety, Tolerability and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Subjects With Severe Complications of Sickle Cell Disease Identifier:
Novartis Reference Number:CADPT03A12101
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

This study is evaluating a genome-edited, autologous, hematopoietic stem and progenitor cell (HSPC) product - OTQ923 to reduce the biologic activity of BCL11A, increasing fetal hemoglobin (HbF) and reducing complications of sickle cell disease.

Sickle Cell Disease
Phase 1, Phase 2
Aug 26, 2020
Oct 31, 2025
2 Years - 40 Years (Child, Adult)




Single intravenous infusion of OTQ923, based on review of data from Part A by Health agencies after a formal interim analysis

Eligibility Criteria

Inclusion Criteria:

Male or female subjects age 2-40 years inclusive
Confirmed diagnosis of sickle cell disease with globin typing (e.g. HbSS, HbSC, HbS/β0-thalassemia or others)
Performance status >70% (Karnofsky for subjects >16 years of age and Lansky for subjects <16 years of age)
At least one of the following indicators of disease severity as defined in the protocol - Vaso-occlusive pain crisis, Acute chest syndrome, Recurrent priapism, prior stroke, receive chronic transfusions, Red cell alloimmunization
Subjects, who have failed, not tolerated or refused hydroxyurea therapy.

Exclusion Criteria:

Available matched related donor for HSCT
Clinically significant active infection
Seropositive for HIV or HTLV
Active known malignancy, myelodysplasia, abnormal cytogenetics or immunodeficiency
Prior HSCT or gene therapy
Known hepatic cirrhosis, bridging hepatic fibrosis or active hepatitis
Protocol defined iron overload
Cerebrovascular procedure within one year, including pial synangiosis for Moyamoya
Severe or progressive arteriopathy or cerebrovascular disease, including Moyamoya

Other protocol defined inclusion/exclusion criteria may apply

Study Location

Novartis Investigative Site



University of Chicago SC - 2


Chicago,Contact: Kathleen Breen (773-702-0102) - [email protected] - James Labelle,60637 - Illinois,United States

Memorial Sloan Kettering Cancer Center


New York,Contact: Elizabeth Mcnair (+1 212 639 3854) - [email protected] - Jaap Jap Boelens,10065 - New York,United States

St Jude Children's Research Hospital


Memphis,Contact: [email protected] - Akshay Sharma,38105-3678 - Tennessee,United States

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

Novartis Pharmaceuticals